Dualsystems Biotech AG is testing the limits of the LRC-TriCEPSTM (CaptiRec) technology using antibodies with different affinities against the same target and cells expressing the target receptor with different expression levels.
Limits-of-LRC-TriCEPS
Details of the assesment see here
Dualsystems Biotech AG Press Release
Schlieren, Switzerland, January 2014: – Dualsystems Biotech AG has announced it will collaborate with another Swiss laboratory, Institute for Biopharmaceutical Research (IBR Inc.) to validate the CaptiRec Triceps/Ligand Receptor Capture Technology. This technology is used to identify the Cell Membrane Receptors on Living Cells.
The partnership will combine the respective strengths of Dualsystems, a leading service provider for protein interaction at the cell membrane and IBR Inc., a GLP-compliant contract research organization specializing in cell-based assays
